Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial ; volume:37 ; number:3 ; day:12 ; month:1 ; year:2023 ; pages:699-701 ; date:3.2023
Leukemia ; 37, Heft 3 (12.1.2023), 699-701, 3.2023
- Creator
-
Zander, Thilo
Pabst, Thomas
Schär, Sämi
Aebi, Stefan
Mey, Ulrich
Novak, Urban
Lerch, Erika
Rhyner Agocs, Gaëlle
Goede, Jeroen
Maniecka, Zuzanna
Hayoz, Stefanie
Rüfer, Axel
Renner, Christoph
Driessen, Christoph
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-023-01809-z
- URN
-
urn:nbn:de:101:1-2410141046354.393976214827
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zander, Thilo
- Pabst, Thomas
- Schär, Sämi
- Aebi, Stefan
- Mey, Ulrich
- Novak, Urban
- Lerch, Erika
- Rhyner Agocs, Gaëlle
- Goede, Jeroen
- Maniecka, Zuzanna
- Hayoz, Stefanie
- Rüfer, Axel
- Renner, Christoph
- Driessen, Christoph
- SpringerLink (Online service)
Other Objects (12)
Accelerated single cell seeding in relapsed multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Accelerated single cell seeding in relapsed multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Accelerated single cell seeding in relapsed multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond